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Abstract
Although vitamin deficiencies are uncommon in Poland or other developed countries, many patients take vitamin supplements. Despite 
the widespread availability of vitamins and the universal belief that vitamins offer health benefits, few publications have addressed their 
role in the prevention and treatment of thyroid diseases. There is some evidence to suggest that the administration of vitamins with 
anti-oxidant properties in patients with hyperthyroidism can decrease the severity of clinical symptoms, and that vitamin D supplementa-
tion can have a beneficial effect on the bone system for these patients. It has also been suggested that patients with autoimmune thyroid 
diseases should be periodically screened for vitamin B12 deficiency. There has been no data to support vitamin supplementation in the 
primary or secondary prevention of thyroid malignancies. (Pol J Endocrinol 2011; 62 (4): 340–344)
Key words: hyperthyroidism, thyroid neoplasms, autoimmune thyroid disorder, vitamins
Streszczenie
Chociaż niedobory witamin w Polsce i krajach rozwiniętych zdarzają się rzadko, bardzo duża grupa pacjentów spożywa suplementy 
witaminowe. Pomimo powszechnego przekonania o korzystnym wpływie na stan zdrowia oraz szerokiej dostępności niewiele jest publi-
kacji określających ich rolę w zapobieganiu i leczeniu chorób tarczycy. Dane z piśmiennictwa sugerują, że u pacjentów z nadczynnością 
tarczycy witaminy o działaniu antyoksydacyjnym mogą zmniejszać nasilenie objawów klinicznych, zaś stosowanie witaminy D może 
korzystnie wpływać na stan kośćca w tej grupie chorych. Sugeruje się także, aby pacjentów z autoimmunologiczną chorobą tarczycy 
okresowo badać w kierunku niedoboru witaminy B12. Nie ma danych uzasadniających suplementację witamin w prewencji pierwotnej 
czy wtórnej nowotworów tarczycy. (Endokrynol Pol 2011; 62 (4): 340–344)
Słowa kluczowe: nadczynność tarczycy, nowotwory tarczycy, autoimmunologiczna choroba tarczycy, witaminy
Krzysztof Sworczak, Department of Endocrinology and Internal Diseases, University Clinical Center, Medical University of Gdańsk, 
ul. Dębinki 7, 80–952 Gdańsk, Poland, tel: +48 (58) 349 28 40, fax: +48 (58) 349 28 41, e-mail: ksworczak@gumed.edu.pl ?
Introduction
Although primary vitamin deficiencies are infre-
quently diagnosed nowadays, sales figures for vita-
min supplements in Poland are high, and continue 
to rise. According to “The healthcare and pharmacy 
market in Poland 2009. Anticipated development 
for the years 2009–2011”, Poland’s pharmacy market 
volume in terms of retail prices exceeds 24 billion 
zloty, 34% of which is generated by over-the-counter 
medications [1]. It is universally accepted that the 
use of vitamin supplements prevents many diseases 
(e.g. infections or malignancies), increases vitality, 
improves mood and enhances treatment of many 
disorders. Despite this belief, and the widespread 
availability of vitamins, their health impact and role 
in the prevention and treatment of diseases remain 
insufficiently understood. 
Aim of the study
We aimed to review the current state of knowledge on 
the possible role of vitamins in patients with thyroid 
disorders. This undertaking has proven exceedingly 
difficult, as few publications have addressed this issue 
in the Polish or the international scientific literature, 
and only a few of those that have done so meet current 
standards of quality and reliability. 
Material and methods
To identify suitable literature, an electronic search 
was performed using PubMed. We used the search 
string “(*vitamin*[Title] OR antioxidant*[Title]) AND 
(*thyroid*[Title] OR goiter*[Title])”. PubMed identified 
117 articles written in English or Polish published up to 
2010. Titles and abstracts were screened, and 36 publica-
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tions that were consistent with the study’s objectives 
were selected for a full-text reading. 
Vitamins with antioxidant properties 
(A, C and E)
Cell homeostasis is maintained in part with the help 
of the oxidoreductive system which limits the dam-
age caused by the so-called reactive oxygen species 
— by-products of the normal metabolism of oxygen. 
Its depletion leads to oxidative stress which results in 
structural and functional damage. Oxidative stress is 
responsible for ageing and plays a role in the develop-
ment of atheromatosis, cancer and Alzheimer’s disease. 
Both hyper- and hypothyroidism have been proven 
to promote cellular oxidative stress by influencing the 
intensity of oxygen reactions. Hyper- and hypothy-
roidism have both been shown to affect concentrations 
of the vitamins involved in scavenging of free radicals 
(usually decreasing their concentrations, although 
study results differ) i.e. vitamins A, C and E. The con-
centrations of those vitamins return to normal after the 
achievement of euthyreosis [2–8]. 
Is supplementation of these vitamins or other anti-
oxidants therefore indicated in patients with thyroid 
disorders? That the answer is ‘yes’ has been suggested 
by the results of animal studies where administration of 
vitamin E in individuals with hyper- or hypothyroidism 
reduced oxidative stress, decreased sensitivity to thyroid 
hormones, and prevented peroxidation of circulating 
LDL lipoproteins [9–11]. 
In a group of patients with hyperthyroidism due to 
Graves’ disease, treated solely with a combination of 
antioxidants (vitamin C, vitamin E, beta-carotene, sele-
nium, zinc, copper), clinical symptoms were reduced to 
a similar extent as in patients treated with thyreostatic 
medications. Moreover, in patients treated with antioxi-
dants, the symptoms of hyperthyroidism subsided more 
rapidly, paralleled by decreased markers of oxidative 
stress. Given that normalization of thyroid hormone 
levels was not observed in this group, the authors sug-
gested that the clinical symptoms of hyperthyroidism 
may reflect free radical toxicity and oxidative stress [12]. 
The beneficial effects of antioxidant supplementation 
(with a preparation similar to that used by Guerra) 
were also seen in a different study. Patients receiving 
antioxidants concomitantly with thyreostatic medica-
tions achieved euthyreosis more rapidly compared to 
patients treated with thyreostatics alone [13]. It seems 
therefore that supplementation of vitamins C and E, and 
possibly other antioxidants, may have beneficial effects 
in patients with hyperthyroidism. This issue requires 
further study and definitive resolution, especially in 
view of other reports suggesting that supplementation 
of vitamins A and E may be associated with increased 
patient mortality [14].
Conversely, it appears that using antioxidants 
in the prevention of thyroid cancer is not justified. 
Although results of a retrospective analysis showed 
decreased incidence of thyroid cancer in patients tak-
ing beta-carotene, vitamin E or vitamin C [15], recent 
meta-analyses and systematic reviews of prospective 
studies unequivocally deny anti-neoplastic effects of 
antioxidant vitamins [16, 17]. 
Vitamin A
The metabolism of vitamin A seems fairly closely con-
nected to the activity of the hypothalamic-pituitary-thy-
roid axis. Animal studies show that vitamin A deficiency 
is associated with decreased thyroid iodine uptake, 
limited synthesis and secretion of hormones, as well 
as thyroid enlargement. The total serum triiodothyro-
nine and thyroxine concentrations increase (common 
transport proteins e.g. transthyretin bind both thyroid 
hormones and the retinol-binding protein, the synthe-
sis of which decreases in vitamin A deficiency). The 
rate of hepatic conversion of thyroxine to triiodothy-
ronine is also decreased. Normally, the secretion of 
thyroid-stimulating hormone (TSH) is regulated by the 
thyroid-hormone-activated receptor and the retinoid X 
receptor. The latter, after binding the ligand (vitamin A) 
binds with its promoter region of DNA encoding the 
beta-subunit of TSH, limiting its expression. Vitamin 
A deficiency is thus associated with increased TSH 
secretion [18].
This issue has not been as well studied in hu-
mans. Studies conducted in areas of endemic iodine 
deficiency have shown that children with goiter and 
concomitant vitamin A deficiency were at less risk of 
developing hypothyroidism. They also had higher 
levels of TSH and thyroxine compared to children 
without vitamin A deficiency. A strong correlation 
was found between goiter size and severity of vitamin 
A deficiency [19]. Monotherapy with vitamin A led to 
a decrease in TSH concentrations and reduction in goiter 
size, with unchanged serum concentrations of thyroid 
hormones [20].
Vitamin B6
Vitamin B6 is a co-enzyme participating in more 
than 100 enzymatic reactions in the human body. 
Clinically, vitamin B6 is essential for the production 
of neurotransmitters, myelin sheaths, hemoglobin, 
myoglobin, and the metabolism of homocysteine. Its 
deficiency leads to dysfunction of the central nervous 
system (manifesting as irritability, mood disturbance, 
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impaired consciousness and seizures), peripheral ner-
vous system (polyneuropathy), as well as anemia and 
hyperhomocysteinemia. 
There are numerous publications in the medical 
literature regarding the role of vitamin B6 in the patho-
genesis and treatment of neurologic, psychiatric and 
hematologic diseases, but few on the subject of vitamin 
B6 in the context of thyroid dysfunction. 
The activity of the hypothalamic-pituitary-thyroid 
axis in the setting of vitamin B6 deficiency has been 
studied in rats. Well-conducted experiments have 
shown that vitamin B6 deficiency leads to hypothy-
roidism resulting from decreased TRH synthesis in the 
hypothalamus. The reversal of vitamin B6 deficiency 
has led to normalization of thyroid hormone levels 
[21]. Over-supplementation of vitamin B6 in human and 
animal studies has led to decreased concentrations of 
the thyroid-stimulating hormone [22, 23]. 
No studies have looked at whether hyperthyroidism 
or hypothyroidism may lead to vitamin B6 deficiency. 
Similarly, there have been no studies on the usefulness 
of vitamin B6 supplements in patients treated with 
antithyroid agents. According to some physicians, 
such treatment may prevent leucopoenia, a fairly com-
mon adverse effect of antithyroid agents. We have not 
found a single publication addressing the efficacy of 
this measure.
Conversely, there are reports of possible adverse ef-
fects of higher than physiologic doses of vitamin B6. The 
daily requirement for vitamin B6 is 2 mg, a level more 
than sufficiently provided by the typical diet. Doses not 
exceeding 200 mg per day (equivalent to two vitamin 
B6 tablets twice daily) are considered safe, whereas 
many cases of sensory neuropathy associated with the 
administration of larger doses have been reported [24].
Vitamin D
Discoveries made during the last few years have greatly 
increased our understanding of the role of vitamin D. 
Its influence is not limited to organs involved in calcium 
homeostasis (such as the gut, bones, kidneys and par-
athyroid glands). Vitamin D receptors have been found 
in more than 35 tissues and it has been demonstrated 
to participate in immune processes, insulin secretion, 
the regulation of the cardiovascular system and the 
development of the central nervous system [25]. Data 
on the metabolism of vitamin D in hyperthyroidism 
is not consistent. Differences result from factors in-
cluding patient selection, dietary vitamin D intake, 
sunlight exposure and seasonal variability of vitamin 
D concentration. Both normal [26–28] and decreased 
[29–31] concentrations of 25-OH-cholecalciferol have 
been found in hyperthyroid patients before treatment. 
A study from Japan including 200 euthyrotic patients 
with Graves’ disease found vitamin D deficiency in 40% 
of women and around 20% of men [32]
It has been demonstrated that hyperthyroidism 
leads to reversible loss of bone mass and temporarily 
increases the risk of femoral neck fracture [33]. This risk 
returns to baseline after approximately a year, whereas 
bone mineral density does not return to baseline until 
one to four years after treatment of hyperthyroidism 
is started [33]. 
In view of the above, the usefulness of vitamin 
D3 supplementation in patients treated for hyperthy-
roidism should be considered, as its possible deficiency 
could negatively influence bone healing. 
Vitamin B12
Vitamin B12 deficiency may result in a number of neu-
rologic, psychiatric, hematologic, gastrointestinal and 
metabolic disturbances (Table I). The commonest etiol-
ogy of decreased absorption of vitamin B12 is atrophic 
gastritis which also increases the risk of developing 
gastric cancer, hyperplasia of enterochromaffin-like cells 
and gastric carcinoid. There is compelling evidence for 
the increased prevalence of vitamin B12 deficiency in the 
population of patients with thyroid disease. 
Centanni et al. examined 62 patients with autoim-
mune thyroid disease (AITD). Patients with increased 
serum gastrin underwent endoscopic, pathologic and 
immunologic testing. Atrophic gastritis was confirmed 
in 22 cases (35%) [34]. Ness-Abramof et al. found de-
creased concentrations of vitamin B12 in 32 out of 115 
(28%) patients with AITD. The authors recommended 
routine measurements of vitamin B12 every 3-5 years 
in these patients. In those with decreased vitamin B12 
concentrations, further management should depend 
on the level of gastrin, as the presence of hypergas-
trinemia is highly suggestive of concomitant atrophic 
Table I. Clinical sequelae of vitamin B12 deficiency
Tabela I. Kliniczne następstwa niedoboru witaminy B12
Neurological symptoms Non-neurological symptoms
Peripheral neuropathy Glossitis 
Subacute combined  Gastrointestinal disturbances
degeneration of spinal cord Weight loss
Focal demyelination Anemia
of white matter in the brain
Optic nerve Impaired fertility
inflammation/atrophy
Psychiatric symptoms Hyperhomocysteinemia
(depression, cognitive deficit, 
psychosis)
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gastritis [35]. The suggested management algorithm is 
summarized in Figure 1. 
Orzechowska-Pawilojc et al. found that both the 
hypothyroid [36] and hyperthyroid [37] state in women 
is associated with lower concentration of vitamin B12 
when compared to a healthy control group. However, 
the authors did not report the higher prevalence of 
vitamin B12 deficiency in the study groups [36, 37].
Summary
It seems that the only indisputable conclusion of the 
current literature regarding the role of vitamins in pa-
tients with thyroid disorders is that this issue requires 
further study. With that in mind, a physician caring 
for patients with thyroid disorders should realize that 
supplementation of antioxidant vitamins probably does 
not prevent thyroid malignancies, but can decrease 
symptoms in patients with hyperthyroidism. It is also 
possible that supplementation of vitamin D in these 
patients accelerates bone healing. There is no scientific 
data justifying supplementation of vitamin B6 in these 
patients. Atrophic gastritis often coexists with autoim-
mune thyroid disease and periodic evaluation of vita-
min B12 levels seems justified in this patient population. 
When counselling patients about the use of vitamin 
supplements, it should be remembered that several 
studies have demonstrated adverse consequences of 
their action. 
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Figure 1. Evaluation of vitamin B12 deficiency in patients with 
autoimmune thyroid disorder (as proposed by Ness-Abramof et al.)
*Schilling test, anti-transglutaminase antibodies, serum 
homocysteine, serum methylmalonic acid 
Rycina 1. Ocena występowania niedoboru witaminy B12 u pacjentów 
z autoimmunologiczną chorobą tarczycy wg Ness-Abramoff i wsp. 
*test Schillinga, przeciwciała przeciwko transglutaminazie, 
stężenie homocyteiny, kwasu metylomalonowego w surowicy
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